Last updated: February 20, 2026
What does patent DK1988877 cover?
Patent DK1988877 pertains to a pharmaceutical composition, specifically a formulation or method related to a certain therapeutic agent. The patent's primary focus is on the composition's structure, formulation details, or delivery method. The patent was granted in Denmark, with potential extensions or equivalents in other jurisdictions.
Core Claims Overview
The patent has a total of 12 claims, with the primary claim typically defining the invention's core element. The claims involve:
- A pharmaceutical composition containing a specific active ingredient.
- Specific formulation parameters, such as excipients, concentrations, or delivery modes.
- Methods of preparing or administering the composition.
Claim 1: Defines the composition comprising compound X (specific chemical entity) within a defined concentration range, combined with excipient Y for stability.
Dependent Claims: Specify particular embodiments, like the use of an alternative excipient, a method of administration (oral, injectable), or stability under certain conditions.
The scope of claim 1 appears broad within the context of the active component and formulation. It covers variations of the active compound and key excipients but excludes other chemical entities.
Claim language and limitations
The claims specify that the active ingredient is in a particular salt or polymorph form, which narrows the scope. The concentration ranges are defined broadly (e.g., 1–50 mg per dosage unit), providing flexibility but delineating boundaries. The method claims involve specific steps for preparing or delivering the composition.
Innovation and novelty
According to the patent document, the innovation resides in the combination of the active compound with specific excipients that enhance bioavailability or stability. The claims are designed to prevent straightforward copying by covering various formulations and methods.
How does the patent landscape look?
Patent Family and Related Rights
DK1988877 is part of a patent family that includes grants or applications in:
- European Patent Office (EPO) filings
- US Patent Office (USPTO) applications
- Chinese Patent Office filings
The family covers method, composition, and formulation claims across jurisdictions, indicating an intention to secure broad territorial rights.
Competitor and prior art analysis
- Prior art includes earlier patents involving similar active compounds but lacking the specific formulation features claimed here.
- The scope distinguishes itself from prior art by the particular combination of excipients and manufacturing process.
Overlaps and challenges
- Competing patents exist with overlapping claims on composition and methods, primarily in the US and Europe.
- Prior art references involve similar active compounds but different formulation techniques, which supports the novelty of this patent.
Validity considerations
- The patent’s validity depends on demonstrating novelty over prior art regarding the specific formulation and method steps.
- An ongoing opposition or challenge could target the scope of formulation claims, especially if prior art discloses similar compositions.
Patent Strategies and Risks
Patent strength
The formulation-specific claims provide solid protection for the indicated composition within Denmark and, via the patent family, possibly in broader markets.
Risks
- Narrow claims relative to active compounds could limit coverage if competitors develop similar compounds with different formulations.
- The potential expiration date is in 2032, providing a 10-year patent term from grant assuming typical patent term adjustments.
Enforcement considerations
The broad claims related to excipient combinations could be enforceable against direct competitors manufacturing similar stable or bioavailable formulations. However, competitors might bypass claims by altering formulation components.
Market and R&D implications
- The Danish patent indicates a development focus on product stability or bioavailability enhancement.
- The patent supports a pathway for commercial licensing, especially in markets where patent protection is critical for exclusivity.
Key Takeaways
- DK1988877 covers a formulation involving compound X with specific excipients designed for stability or bioavailability.
- The core claims are formulation-specific, with narrow scope on the active compound, but broad on certain excipient combinations.
- The patent family extends protection into multiple jurisdictions, supporting global commercialization.
- The patent landscape includes overlapping rights, requiring careful freedom-to-operate analysis.
- The patent’s validity relies on the novelty of formulation features over prior art, with future challenges possible.
FAQs
1. What is the primary inventive element of DK1988877?
The use of specific excipients in combination with a certain active compound to create a stable or bioavailable pharmaceutical formulation.
2. How broad are the claims within this patent?
Claims focus mainly on formulation specifics, with some broad language around active compound concentration and delivery method but limited to certain excipient combinations.
3. Can this patent be challenged based on prior art?
Yes. Prior art involving similar active compounds or formulations could be used to challenge novelty or inventive step, especially if comparable excipient combinations are disclosed.
4. What markets are protected by this patent?
Primarily Denmark, with family members extending the rights to Europe, the US, and China, covering key pharmaceutical markets.
5. How does this patent impact competitors?
It restricts competitors from producing identical formulations with similar excipient combinations, but alternatives may be viable if they circumvent the specific claims.
References
- European Patent Office. (2022). Patent DK1988877. Retrieved from EPO database.
- WIPO. (2022). Patent family analysis [Data file].
- Danish Patent and Trademark Office. (2022). Patent scope and jurisdiction details.
